Spanish drugmaker Grifols has been awarded a $21 million grant from the Michael J Fox Foundation to support a pilot study to ...

The takeover deliberations come shortly after Grifols completed the sale of its 20% stake in Chinese blood products unit Shanghai RAAS to Haier, a deal first announced in 2020, raising cash of ...

U.S.-based investment fund Mason Capital said on Monday it had sent a letter to Spain's stock market regulator CNMV demanding ...

The Catalan blood products company has received a $21 million grant from the Michael J. Fox Foundation (MJFF) for Parkinson's ...

Grifols SA engages in the production of plasma ... The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment ...

BARCELONA, Spain, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Grifols (MCE: GRF, MCE: GRF.P, and NASDAQ: GRFS), a global healthcare company and leading producer of plasma ...

Spanish pharma Grifols is leveraging its massive collection of plasma samples to look for early biomarkers of Parkinson’s disease (PD) thanks to a $21 million grant from the Michael J.

"We urge the CNMV to consider the benefits to all Grifols shareholders from improved disclosure," Mason Capital said. As global markets navigate a mixed economic landscape marked by declining ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

(Bloomberg) -- Grifols SA sued Gotham City Research over a report alleging the company has overstated profit and misstated its accounting. Gotham City Research, run by Daniel Yu and Cyrus de Weck ...

The unique plasma assets serve as the foundation of the Chronos-PD program, driving advanced research at Grifols subsidiary Alkahest, which is leading the initiative given its specialization in the ...